Drug Patents owned by Horizon Pharma Usa

1. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925156 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9198882 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9192590 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9925158 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9925157 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9198882

(Pediatric)

HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US9192590

(Pediatric)

HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US8026284 HORIZON PHARMA USA Enterically coated cystamine, cysteamine and derivatives thereof Sep, 2027

(4 years from now)

US8026284

(Pediatric)

HORIZON PHARMA USA Enterically coated cystamine, cysteamine and derivatives thereof Mar, 2028

(5 years from now)

US9233077 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9173851 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9233077

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

US9173851

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

US10143665 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10548859 HORIZON PHARMA USA Methods for storing Cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10328037 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10905662 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription
EQ 300MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.